Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E–Deficient Mice
Author(s) -
Tomoya Hara,
Phạm Trần Phương,
Daiju Fukuda,
Koji Yamaguchi,
Chie Murata,
Sachiko Nishimoto,
Shusuke Yagi,
Kenya Kusunose,
Hirotsugu Yamada,
Takeshi Soeki,
Tetsuzo Wakatsuki,
Issei Imoto,
Michio Shimabukuro,
Masataka Sata
Publication year - 2018
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.033544
Subject(s) - medicine , inflammation , apolipoprotein b , apolipoprotein e , receptor , vascular wall , protease , immunology , disease , cholesterol , enzyme , biochemistry , biology
Background: The coagulation system is closely linked with vascular inflammation, although the underlying mechanisms are still obscure. Recent studies show that protease-activated receptor (PAR)-2, a major receptor of activated factor X, is expressed in both vascular cells and leukocytes, suggesting that PAR-2 may contribute to the pathogenesis of inflammatory diseases. Here we investigated the role of PAR-2 in vascular inflammation and atherogenesis. Methods: We generated apolipoprotein E-deficient (ApoE -/- ) mice lacking systemic PAR-2 expression (PAR-2 -/- ApoE -/- ). ApoE-/- mice, which lack or express PAR-2 only in bone marrow (BM) cells, were also generated by BM transplantation. Atherosclerotic lesions were investigated after 20 weeks on a Western-type diet by histological analyses, quantitative reverse transcription polymerase chain reaction, and Western blotting. In vitro experiments using BM-derived macrophages were performed to confirm the proinflammatory roles of PAR-2. The association between plasma activated factor X level and the severity of coronary atherosclerosis was also examined in humans who underwent coronary intervention.Results: PAR-2 -/- ApoE -/- mice showed reduced atherosclerotic lesions in the aortic arch (P <0.05) along with features of stabilized atherosclerotic plaques, such as less lipid deposition (P <0.05), collagen loss (P <0.01), macrophage accumulation (P <0.05), and inflammatory molecule expression (P <0.05) compared withApoE -/- mice. Systemic PAR2 deletion inApoE -/- mice significantly decreased the expression of inflammatory molecules in the aorta. The results of BM transplantation experiments demonstrated that PAR-2 in hematopoietic cells contributed to atherogenesis inApoE -/- mice. PAR-2 deletion did not alter metabolic parameters. In vitro experiments demonstrated that activated factor X or a specific peptide agonist of PAR-2 significantly increased the expression of inflammatory molecules and lipid uptake in BM-derived macrophages from wild-type mice compared with those from PAR-2–deficient mice. Activation of nuclear factor-κB signaling was involved in PAR-2–associated vascular inflammation and macrophage activation. In humans who underwent coronary intervention, plasma activated factor X level independently correlated with the severity of coronary atherosclerosis as determined by Gensini score (P <0.05) and plaque volume (P <0.01).Conclusions: PAR-2 signaling activates macrophages and promotes vascular inflammation, increasing atherosclerosis inApoE -/- mice. This signaling pathway may also participate in atherogenesis in humans.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom